Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

10372	Companies
216173	Keywords
145882	Articles
114461	Press releases

Home
Companies
Jaguar Health, Inc.

BRIEF

published on 04/07/2026 at 14:35, 1 month 2 days ago

Jaguar Health annonce des résultats financiers mitigés pour 2025

Jaguar Health Résultats Financiers 2025 Appel Du Nasdaq Accord Futur Sur Le Pakistan Médicaments Crofelemer
BRIEF

published on 04/07/2026 at 14:35, 1 month 2 days ago

Jaguar Health Reports Mixed Financial Results for 2025

Jaguar Health Financial Results 2025 Crofelemer Drugs Nasdaq Appeal Future Pak Agreement
PRESS RELEASE

published on 04/07/2026 at 14:30, 1 month 2 days ago

Jaguar Health Reports 2025 Financials
Jaguar Health, Inc. reports a 5% increase in net revenue in Q4 2025 compared to Q3 2025. Company receives $16M upfront payment from Future Pak for license agreement. Financial results include revenue breakdown and operational expenses

Financial Results Jaguar Health License Agreement Q4 2025 Net Revenue Increase
BRIEF

published on 04/02/2026 at 15:05, 1 month 7 days ago

Jaguar Health co-organise la conférence de gastro-entérologie pédiatrique

Gastro-entérologie Pédiatrique Résultats De L'étude Clinique Développement Crofelemer Insuffisance Intestinale Congrès D'élite En Pédiatrie Et Gastro-entérologie
BRIEF

published on 04/02/2026 at 15:05, 1 month 7 days ago

Jaguar Health Co-Sponsors Pediatric Gastroenterology Conference

Pediatric Gastroenterology Clinical Study Results Crofelemer Development ELITE PED-GI Congress Intestinal Failure
PRESS RELEASE

published on 04/02/2026 at 15:00, 1 month 7 days ago

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Jaguar Health's crofelemer program targeting intestinal failure shows promising results with reductions in parenteral support for pediatric patients. Company sponsors ELITE PED-GI Congress in Abu Dhabi

Jaguar Health ELITE PED-GI Congress Intestinal Failure Parenteral Support Reduction Crofelemer Program
BRIEF

published on 03/24/2026 at 14:44, 1 month 16 days ago

Jaguar Health Inc. reçoit une recommandation d'achat de la part de First Berlin Equity Research.

Jaguar Health Premier Berlin Potentiel Du Marché Évaluation D'achat Innovation Dans Le Secteur De La Santé
BRIEF

published on 03/24/2026 at 14:44, 1 month 16 days ago

Jaguar Health Inc Receives Buy Rating from First Berlin Equity Research

BUY Rating Jaguar Health Healthcare Innovation Market Potential First Berlin
PRESS RELEASE

published on 03/24/2026 at 14:39, 1 month 16 days ago

Original-Research: Jaguar Health Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research initiates coverage on Northwest Biotherapeutics Inc., providing insights into the company's late-stage oncology developments including the promising DCVax-L immunotherapy for glioblastoma

First Berlin Equity Research Northwest Biotherapeutics Inc. DCVax-L Immunotherapy Late-stage Oncology Developments USD 1.00 Price Target
BRIEF

published on 03/18/2026 at 14:05, 1 month 22 days ago

La FDA soutient la prolongation de l'essai clinique du crofélémer de Jaguar Health pour le MVID

Jaguar Health Approbation De La FDA Traitement MVID Procès Crofelemer Trouble Pédiatrique

Accesswire

Published on 05/09/2026 at 01:55, 1 day 9 hours ago

Prospect Ridge Announces Board Resignation
Published on 05/09/2026 at 01:40, 1 day 9 hours ago

Findev Inc. Issues Corrective Disclosure
Published on 05/09/2026 at 01:30, 1 day 9 hours ago

Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 1 day 10 hours ago

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:01, 1 day 11 hours ago

Water Ways Announces Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 05/09/2026 at 19:05, 15 hours 51 minutes ago

LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 1 day 14 hours ago

EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 1 day 15 hours ago

EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 1 day 15 hours ago

Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/08/2026 at 18:29, 1 day 16 hours ago

Designated Person Notification

Les Echos

Published on 05/07/2026 at 19:15, 2 days 15 hours ago

2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 2 days 15 hours ago

Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 2 days 15 hours ago

Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 2 days 15 hours ago

Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 2 days 15 hours ago

ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE